June 5, 2015

The company is fighting an injunction that’s keeping Sandoz’s Zarxio from becoming the first biosimilar sold in the United States.

 
June 4, 2015

Sandoz has announced that it is introducing guanfacine hydrochloride extended-release tablets, a generic version of Intuniv, in 1-, 2-, 3- and 4-mg dosages.

April 24, 2015

Sandoz on Friday announced the launch of levoleucovorin injection ready-to-use single use vial, a generic version of Fusilev, which is marketed by Spectrum Pharmaceuticals. 

April 16, 2015

Sandoz on Thursday introduced a new generic MS therapy.

April 7, 2015

The Canadian Generic Pharmaceutical Association on Tuesday established a new Biosimilars Board. 

 

 

March 31, 2015

Teva Pharmaceutical Industries announced the launch of generic Exforge (amlodipine and valsartan) tablets, which are indicated for the treatment of hypertension. 

 

February 12, 2015

Sandoz on Thursday launched telmisartan tablets, the generic version of Micardis from Boehringer Ingelheim. The drug is used to treat hypertension, the company said.

 

December 22, 2014

Sandoz has announced the U.S. market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot, which is marketed by Novartis Pharmaceuticals.

November 10, 2014

Sandoz last week announced the launch of a generic version of cyclophosphamide injection, USP. Sandoz is launching the drug through collaboration with Jiangsu Hengrui Medicine Co., which owns the product's abbreviated new drug application. 

October 30, 2014

Sandoz, through its branded dermatology business PharmaDerm, and Medigene AG on Thursday announced a promotion agreement with Women's Choice Pharmaceuticals for Veregen (sinecatechins) ointment, 15% strength. 

October 7, 2014

Sandoz announced the launch of its dexmedetomidine hydrochloride injection, a generic version of Precedex from Hospira. 

September 23, 2014

Sandoz announced the launch of Kerydin (tavaborole) topical solution, 5% in the United States. Kerydin is the first oxaborole antifungal for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes, the company stated. 

September 2, 2014

Sandoz last week announced the U.S. market introduction of decitabine for injection, a generic version of Eisai’s Dacogen.

July 28, 2014

The Food and Drug Administration has accepted a license application by Sandoz, Novartis' generics company, for a potential generic biologic drug, the company announced Monday.

July 21, 2014

Sandoz on Monday announced an agreement with Anacor Pharmaceuticals to obtain exclusive rights to commercialize Kerydin (tavaborole) topical solution, 5%, through its branded dermatology business, PharmaDerm.

July 14, 2014

Sandoz on Monday announced the introduction of tobramycin inhalation solution, USP into the U.S. market. The drug is an authorized generic version of Tobi from Novartis.

July 7, 2014

Sandoz announced the launch of valsartan tablets, an authorized generic version of Diovan tablets which is used for the treatment of high blood pressure.

June 18, 2014

Canada’s Federal Court ruled recently that the country’s Patented Medicine Prices Review Board — a federal tribunal that regulates pricing on branded medicines — could not extend price-control measures to cover generic drug companies, according to published reports.

June 10, 2014

Canada’s Federal court ruled recently that the country’s Patented Medicine Prices Review Board – a federal tribunal that regulates pricing on branded medicines – could not extend price control measures to cover generic drug companies.

June 3, 2014

Sandoz on Tuesday announced an agreement with Upsher-Smith to obtain exclusive U.S. distribution rights for its branded potassium chloride line of products, Klor-Con, and market them under the Sandoz name.

May 15, 2014

Teva Pharmaceutical was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis, drug 10 days before the patent on the medication expires, according to a Bloomberg report published Thursday morning.

April 28, 2014

Sandoz on Monday announced the introduction of its adapalene 0.3% gel, a generic version of Differin gel, 0.3% from Galderma Labs.

April 22, 2014

Impax Labs on Monday announced the its board of directors appointed G. Frederick Wilson as the company's president and CEO, effective April 29.

April 2, 2014

Sandoz on Tuesday announced the U.S. market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex Ointment.